Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673722 | 0.89 | GPR119 (0.58) | ALDH1A1MAPTCTSBGPR119HTT | |
| SCHEMBL1673851 | 0.81 | GPR119 (0.57) | ALDH1A1MAPTCTSBGPR119HTT | |
| SCHEMBL6041129 | 0.80 | GPR119 (0.66) | ALDH1A1MAPTCTSBGPR119HTT | |
| SCHEMBL1673977 | 0.79 | MAPT (0.52) | ALDH1A1MAPTCTSBGPR119TSHR | |
| SCHEMBL5261829 | 0.79 | GPR119 (0.45) | ALDH1A1MAPTCTSBGPR119TSHR | |
| SCHEMBL1673701 | 0.77 | GPR119 (0.58) | ALDH1A1MAPTCTSBGPR119TSHR | |
| SCHEMBL390558 | 0.77 | GPR119 (0.65) | ALDH1A1MAPTGPR119HTTMEN1 | |
| SCHEMBL1673807 | 0.77 | GPR119 (0.44) | GPR119SMN1; SMN2 | |
| SCHEMBL386411 | 0.77 | GPR119 (0.77) | ALDH1A1MAPTCTSBGPR119HTT | |
| SCHEMBL1673779 | 0.76 | GPR119 (0.78) | ALDH1A1MAPTGPR119TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | UGT1A1, GPR119, UGT1A3 | ALDH1A1 169/4885MAPT 4467/4885CTSB 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.